Page 1

ASX MEDIA RELEASE 27 August 2026 CLARITY PHARMACEUTICALS Appendix 4E Preliminary Final Report - 30 June 2026 Clarity Pharmaceuticals Ltd ( ASX : CU6 ) ( " Clarity " ) , a clinical stage radiopharmaceutical company focused on the treatment of serious diseases , is pleased to announce it has released its Appendix 4E : Preliminary Final Report for the year ending 30 June 2026 . The Appendix 4E is attached to this release . This release is authorised by the board of directors of Clarity . For more information , please contact : Dr Alan Taylor Executive Chairman ataylor@claritypharm.com Lisa Sadetskaya Director , Corporate Communications lisa@claritypharm.com About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease . The Company is a leader in innovative radiopharmaceuticals , developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer . www.claritypharmaceuticals.com/ CLARITY ACN : 143 005 341 PHARMACEUTICALS T : +61 ( 0 ) 2 9209 4037 LIMITED E : investor@claritypharmaceuticals.com W : www.claritypharmaceuticals.com